首頁師資〉教師指導學生

張明熙

張明熙  (Chang, Ming-shi,  Ph.D.)

生化所教授 分機:5677 E-mail: mschang@mail.ncku.edu.tw 

個人網頁:http://www.ncku.edu.tw/biochem/profs/mschang/introduc.htm

研究興趣

  本實驗室的研究計劃主要目標是由人體基因計劃的基因庫中去篩選有價值的新分子並鑑定該分子的生物功能,再進一步把該新分子研發成醫學新藥。研究的範圍包括 cytokines, cytokine receptors和 chemokines。藉這些新分子的研發,希望能對癌症或免疫系統失調或骨質疏鬆症或神經系統失調等疾病加以治療。 

近五年代表作 

  1. Hsing CH, Cheng HC, Hsu YH, Chan CH, Yeh CH, Li CF,and Chang MS*Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clinical Cancer Research 2012 Feb 1;18(3):713-25 (IF 7.6 ranking: 5%)
  2. HsuYH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, and Chang MS*Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models  Journal of Immunology 2012 Feb 15;188(4):1981-91 (IF 5.75 ranking 14%)
  3. Hsu YH, Hsieh PP, Chang MS.Interleukin-19 blockade attenuates collagen- induced arthritis in rats. Rheumatology. 2012 Mar; 51(3): 434-42
  4. Hsu YH,Chen WY,Chan CH,Wu CH, Sun ZJ, Chang MS*. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med. 2011, 208(9):1849-61 (IF 14.77 ranking 1.8%)
  5. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010 Nov;62(11):3311-21